Response to comment on ‘Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial’

被引：0
|
作者：
M L Subramanian
机构：
[1] Boston University School of Medicine and the VA Boston Healthcare System,Department of Ophthalmology
来源：
Eye | 2011年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：820 / 820
相关论文
共 50 条
  • [31] Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration
    Ying, Gui-shuang
    Huang, Jiayan
    Maguire, Maureen G.
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Daniel, Ebenezer
    Klein, Michael
    Pieramici, Dante
    Wells, John
    Martin, Daniel F.
    OPHTHALMOLOGY, 2013, 120 (01) : 122 - 129
  • [32] Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
    Jacob, Julie
    Brie, Heidi
    Leys, Anita
    Levecq, Laurent
    Mergaerts, Filip
    Denhaerynck, Kris
    Vancayzeele, Stefaan
    Van Craeyveld, Eline
    Abraham, Ivo
    MacDonald, Karen
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (01) : 81 - 90
  • [33] Six-year outcomes in neovascular age-related macular degeneration with ranibizumab
    Julie Jacob
    Heidi Brié
    Anita Leys
    Laurent Levecq
    Filip Mergaerts
    Kris Denhaerynck
    Stefaan Vancayzeele
    Eline Van Craeyveld
    Ivo Abraham
    Karen Mac Donald
    International Journal of Ophthalmology, 2017, 10 (01) : 81 - 90
  • [34] Thalidomide polyneuropathy: A prospective double-masked placebo-controlled study in an elderly population with age-related macular degeneration
    Khella, SL
    Souayah, N
    NEUROLOGY, 2001, 56 (08) : A208 - A209
  • [35] External beam irradiation of subfoveal choroidal neovascularization complicating age related macular degeneration: 1 year results of a prospective, double-masked, randomized pilot clinical trial.
    Marcus, DM
    Sheils, WC
    McIntosh, SB
    Johnson, MH
    Leibach, DB
    Alexander, J
    Maguire, AM
    Samy, CN
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S179 - S179
  • [36] Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration Two-Year Results
    Martin, Daniel F.
    Maguire, Maureen G.
    Fine, Stuart L.
    Ying, Gui-shuang
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Redford, Maryann
    Ferris, Frederick L.
    OPHTHALMOLOGY, 2020, 127 (04) : S135 - S145
  • [37] Cost-effectiveness of ranibizumab and bevacizumab for neovascular age-related macular degeneration: 1 year IVAN results
    Rogers, Chris
    Dakin, Helen
    Wordsworth, Sarah
    Abangma, Giselle
    Raftery, James
    Harding, Simon
    Chakravarthy, Usha
    Lotery, Andrew
    Downes, Susan
    Reeves, Barnaby
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [38] Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab
    de Geus, Stefan J. R.
    Jager, Martine J.
    Luyten, Gre P. M.
    Dijkman, Greet
    ACTA OPHTHALMOLOGICA, 2013, 91 (05) : E411 - E413
  • [39] Bevacizumab vs ranibizumab treatment for age-related macular degeneration - A head-to-head comparison is needed
    Jampol, Lee M.
    ARCHIVES OF OPHTHALMOLOGY, 2007, 125 (04) : 557 - 558
  • [40] A Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to a Treat and Extend Protocol: 1-Year Results from the LUCAS Study
    Berg, Karina
    OPHTHALMOLOGICA, 2014, 232 : 18 - 19
12345